Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capromab - Cytogen Corporation

Drug Profile

Capromab - Cytogen Corporation

Alternative Names: 111In CYT 356; Capromab pendetide; CYT 356; indium (111In) labeled capromab pendetide; Indium-111-CYT-356; lndium-CYT-356; ProstaScint

Latest Information Update: 14 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytogen Corporation
  • Class Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 01 Apr 2019 Hybridyne Imaging Technologies completes a clinical trial in Prostate cancer (Diagnosis) in Canada (NCT02786459)
  • 06 Jun 2016 Hybridyne Imaging Technologies initiates enrolment in a clinical trial in Prostate cancer (Diagnosis) in Canada
  • 02 Mar 2016 Hybridyne Imaging Technologies plans a clinical trial for Prostate cancer (Diagnosis) in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top